抗结核治疗中的治疗药物监测:系统综述
该系统综述纳入35项观察性研究,覆盖21个国家及成人、儿童、耐多药/广泛耐药结核和HIV合并感染人群,评估异烟肼、利福平等一线药物及贝达喹啉、利奈唑胺等二线药物的治疗药物监测(TDM)。综述涉及血浆、干血斑、尿液、毛发和外周血单核细胞等多种基质及LC-MS/MS、HPLC、UPLC等分析技术,结论认为TDM通过个体化给药提高疗效与安全性,但需进一步研究标准化方案。
要点
- TDM可个体化调整抗结核药物剂量,改善疗效与安全性。
- 监测基质包括血浆、干血斑、尿液、毛发和外周血单核细胞。
- 常用分析技术为LC-MS/MS、HPLC和UPLC。
核心结论
- 评估多种生物基质和分析技术表明,TDM通过个体化药物剂量提高治疗疗效和安全性。
- 需要进一步研究以标准化TDM方案并探索新方法以改善结核治疗结局。
研究设计与样本
- 系统综述纳入35篇观察性研究,覆盖21个国家,涉及成人、儿童、耐多药/广泛耐药结核及HIV合并感染人群。
主要发现
- 研究涵盖异烟肼、利福平等一线药物及贝达喹啉、利奈唑胺等二线药物。
- 采样基质包括人血浆、干血斑、尿液、毛发和外周血单核细胞。
- 分析技术包括LC-MS/MS、HPLC和UPLC,用于确保药物水平的精确测量。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: The treatment of tuberculosis (TB) depends on anti-TB drugs to eradicate the infection and prevent its transmission. Variability in drug metabolism, interactions, and adherence can affect treatment efficacy. Therapeutic drug monitoring (TDM) is essential for optimizing treatment by adjusting dosages. This systematic review aimed to assess the effectiveness of TDM for anti-TB drugs using different biological matrices and to reveal the techniques employed in TDM. METHODS: A systematic review included studies reporting anti-TB drug monitoring with relevant analytical methods. Reports were screened to include the type of study, population, countries, sample size, anti-TB drugs, biological matrices, sampling time, and analytical methods. RESULTS: This systematic review includes 35 articles that focus on methods for quantifying anti-TB drugs in clinical settings through observational studies. The research covers 21 countries, including China, USA, India, Italy, Indonesia, the Republic of Korea, and Germany, and involves diverse populations such as adults, children, and patients with MDR- and XDR-TB, as well as those with HIV co-infection. The studies examine a range of anti-TB drugs, from first-line treatments like isoniazid and rifampicin to second-line options such as bedaquiline and linezolid. Various sampling methods were employed, including human plasma, dried blood spots, urine, hair, and peripheral blood mononuclear cells, with analytical techniques such as LC-MS/MS, HPLC, and UPLC utilized to ensure precise measurement of drug levels. CONCLUSIONS: The assessment of diverse biological matrices and analytical techniques demonstrates that TDM improves treatment efficacy and safety by individualizing drug dosages. Further research is essential to standardize TDM protocols and investigate novel methodologies to enhance TB treatment outcomes.
引用
- Metarfi Y, Chellal W, Ben Khadda Z, et al. Therapeutic drug monitoring in anti-tuberculosis treatment: a systematic review. J Antimicrob Chemother. 2025. PMID: 40256853. doi:10.1093/jac/dkaf126
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。